EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

Peters, M. J. L. et al. (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases, 69(2), pp. 325-331. (doi:10.1136/ard.2009.113696) (PMID:19773290)

Peters, M. J. L. et al. (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases, 69(2), pp. 325-331. (doi:10.1136/ard.2009.113696) (PMID:19773290)

Full text not currently available from Enlighten.

Abstract

Objectives: To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Methods: A multidisciplinary expert committee was convened as a task force of the EULAR Standing Committee for Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists and epidemiologists, representing nine European countries. Problem areas and related keywords for systematic literature research were identified. A systematic literature research was performed using MedLine, Embase and the Cochrane library through to May 2008. Based on this literature review and in accordance with the EULAR's "standardised operating procedures'', the multidisciplinary steering committee formulated evidence-based and expert opinion-based recommendations for CV risk screening and management in patients with inflammatory arthritis. Results: Annual CV risk assessment using national guidelines is recommended for all patients with RA and should be considered for all patients with AS and PsA. Any CV risk factors identified should be managed according to local guidelines. If no local guidelines are available, CV risk management should be carried out according to the SCORE function. In addition to appropriate CV risk management, aggressive suppression of the inflammatory process is recommended to further lower the CV risk. Conclusions: Ten recommendations were made for CV risk management in patients with RA, AS and PsA. The strength of the recommendations differed between RA on the one hand, and AS and PsA, on the other, as evidence for an increased CV risk is most compelling for RA

Item Type:Articles
Keywords:ANKYLOSING-SPONDYLITIS cardiovascular risk CONVERTING ENZYME-INHIBITION CORONARY-HEART-DISEASE DENSITY-LIPOPROTEIN CHOLESTEROL guidelines hypertension LIPID PROFILES LONG-TERM MANAGEMENT MYOCARDIAL-INFARCTION pharmacotherapy PLASMA HOMOCYSTEINE POPULATION-BASED COHORT PSORIATIC-ARTHRITIS RHEUMATOID-ARTHRITIS RISK risk factors RISK-FACTOR RISK-FACTORS SCORE
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Sattar, Professor Naveed
Authors: Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., Semb, A., Sidiropoulos, P., Kitas, G., Smulders, Y. M., Soubrier, M., Szekanecz, Z., Sattar, N., and Nurmohamed, M.T.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Annals of the Rheumatic Diseases
Publisher:B M J Group
ISSN:0003-4967
ISSN (Online):1468-2060

University Staff: Request a correction | Enlighten Editors: Update this record